الفهرس 
EpidemiologyOnly 14 pages are availabe for public view
 |  | from | 266 |  |  |
| | | from | 266 | | |
Abstract
HCC is a major cause of morbidity and mortality; it is the seventh most common cancer world-wide, and the second leading cause of cancer related deaths. Its prognosis is poor and early detection is of great importance.
AFP is the currently available traditional marker for the detection of hepatocellular carcinoma. Its poor sensitivity make it unsatisfactory for this purpose and suggests an urgent need for novel biomarkers for early stage HCC detection.
Talin-1 is identified cytoplasmic protein partner of integrins that is important component of focal adhesion complexes of adherent cells. Talin-1 has been identified as a novel molecular marker for HCC progression and has revealed that its up regulation is associated with HCC progression showing that it may serve as a prognostic marker.
The present study directed towards evaluation the role of serum Talin-1 as a novel biomarker for the diagnosis of HCC and comparison between this marker and the traditional marker AFP.
This study was conducted in Gastroenterology Department, El Demardash Hospital, Ain Shams University.
The study included 96 subjects classified into three groups. Group(I): included 40 patients with liver cirrhosis without HCC,(28) males and (12) females. group (II): included 40 patients with liver cirrhosis with HCC as diagnosed by triphasic CT,(28) males and (12) females. group (III): included 16 healthy volunteers, age and gender matched with the diseased groups served as control,(12)males and (4) females.
All subjects in the study were subjected to the following assessment: full history taking, full general clinical examination, abdominal ultrasonography, triphasic CT abdomen to diagnose hepatocellular carcinoma, liver function tests, HCV antibody, HBsAg, AFP and serum Talin-1 by enzyme linked immune-sorbent assay(ELISA).
The results of this study revealed that:
As regard age and sex, there was no significant difference between the studied groups.
There were highly significant statistical difference between the studied groups as regard (ALT, AST, ALP, bilirubin, albumin and INR) (P< 0.001).
As regard AFP level, the highest level was observed among HCC group, followed by cirrhosis group, and the lowest level observed among control group.
There was a statistically significant increase in serum Talin-1 levels in patient groups as compared to control group.
The highest level was observed among cirrhosis with HCC group, followed by cirrhosis without HCC group, and the lowest level observed among control group. There was significant relation between Talin-1 and each of the tumor number, portal vein invasion and prescence of ascites but no relation between it and the tumor size in HCC patients.
In all patients, there were a significant positive correlation between Talin-1 and ALT, AST, ALP, Bilirubin, INR,urea and AFP, and a significant negative correlation between Talin-1 and albumin, creatinine, hemoglobin, WBCs and platelets.
Serum Talin -1 level has a high sensitivity in prediction of HCC similar to AFP so; it has a good diagnostic value in diagnosis of HCC.
Measuring both serum Talin 1 and AFP levels enhance the diagnostic sensitivity in early diagnosis of HCC.